1. Home
  2. MATH vs CUE Comparison

MATH vs CUE Comparison

Compare MATH & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

N/A

Current Price

$1.21

Market Cap

82.9M

Sector

Finance

ML Signal

N/A

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$0.29

Market Cap

27.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
CUE
Founded
2015
2014
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.9M
27.1M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
MATH
CUE
Price
$1.21
$0.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.00
AVG Volume (30 Days)
94.7K
366.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
35.14
EPS
N/A
N/A
Revenue
N/A
$9,287,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$25.00
P/E Ratio
$3.10
N/A
Revenue Growth
N/A
69.16
52 Week Low
$1.14
$0.23
52 Week High
$4.17
$1.21

Technical Indicators

Market Signals
Indicator
MATH
CUE
Relative Strength Index (RSI) 31.34 39.68
Support Level N/A $0.28
Resistance Level $4.04 $0.36
Average True Range (ATR) 0.10 0.02
MACD 0.02 0.00
Stochastic Oscillator 29.39 25.81

Price Performance

Historical Comparison
MATH
CUE

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: